23030-39-9

Usage

Uses

Used in Pharmaceutical Industry:
2,3,5-Trimethoxybromobenzene is used as an intermediate in the synthesis of 2,3,5-Trimethoxyamphetamine (T896885), a derivative of Amphetamine (A634240). 2,3,5-Trimethoxybromobenzene is known for its central nervous system (CNS) stimulant and anorexic properties, making it a controlled substance in the category of stimulants.
In the synthesis process, 2,3,5-Trimethoxybromobenzene plays a crucial role in the production of the desired amphetamine derivative, which can be utilized for its stimulant and appetite-suppressing effects. The compound's structural features allow for further chemical modifications and the development of new drugs with potential therapeutic applications.

Upstream product

• 2973-76-4 5-bromo-4-hydroxy-3-methoxybenzaldehyde 
• 61654-67-9 2,5-dihydroxy-3-methoxy-1-bromobenzene 
• 77-78-1 dimethyl sulfate 
• 74-88-4 methyl iodide 
• 100668-76-6 Formic acid 3-bromo-4,5-dimethoxy-phenyl ester 
• 6948-30-7 5-bromoveratralaldehyde 
• 93092-14-9 1-bromo-5-hydroxy-2,3-dimethoxybenzene 

Downstream Products

• 5556-84-3 2,3,5-trimethoxy-benzaldehyde 
• 27613-31-6 2,4,5-trihydroxy-6-methylbenzoic acid 
• 100761-40-8 (+/-)-2-(1,5-dimethyl-4-hexenyl)-3-methoxy-5-methyl-2,5-cyclohexadiene-1,4-dione <(+/-)-O-methylperezone> 
• 79786-37-1 2,4,5-trimethoxy-6-methylbenzoic acid 
• 114992-40-4 methyl 2,4,5-trimethoxy-6-methylbenzoate 
• 100668-78-8 (+/-)-leucoperezone trimethyl ether 
• 114992-39-1 2-bromo-3-methyl-1,4,5-trimethoxybenzene 
• 114992-41-5 methyl 2-bromomethyl-3,4,6-trimethoxybenzoate 
• 100668-77-7 (+/-)-8-hydroxyleucoperezone 
• 482627-32-7 1,4-Bis[5-(2,3,5-trimethoxyphenyl)-pyridin-2-yl]hexahydro-1,4-diazepine 
• 36873-96-8 2,3,5-trimethoxybenzoic acid 
• 1354708-11-4 4'-decyl-2-methoxy-2'-(2'',3'',5''-trimethoxybenzoyloxy)acetophenone 
• 1352034-36-6 C₃₃H₄₁F₃O₆ 
• 1352034-35-5 C₃₃H₄₁F₃O₆ 

Relevant academic research and scientific papers

ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS OR PRECURSORS THEREOF

Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.

Synthesis of polyhydroxylated flavonoids bearing a lipophilic decyl tail as potential therapeutic antioxidants

Antioxidants have potential for the treatment of stroke and neurodegeneration, and chimeric compounds that combine a flavon-3-ol head group related to myricetin and a lipophilic decyl tail are known to protect membranes from oxidative damage at least as well as vitamin E. New flavon-3-ols that are highly hydroxylated in the B ring in ways not found in natural flavon-3-ols and bearing a lipophilic decyl tail have been prepared from trimethoxy-and tetramethoxybenzoic acids accessed by lithiation-carboxylation reactions. Direct enolate acylation was preferred over Baker-Venkataraman rearrangement when there were methoxy groups at both the 2-and the 6-position of the benzoic acid derivatives.

2-Amino-4-methyl-5-phenylethyl substituted-7-N-benzyl-pyrrolo[2,3-d] pyrimidines as novel antitumor antimitotic agents that also reverse tumor resistance

Gangjee et al. recently reported a novel series of 2-amino-4-methyl-5- phenylethyl substituted-7-benzyl-pyrrolo[2,3-d]pyrimidines, some of which exhibited two digit nanomolar antitumor and antimitotic activity and were not subject to P-glycoprotein (Pgp)

Synthesis of the proposed structure of queenslandon

The proposed structure of the benzolactone queenslandon (6) was synthesized utilizing a triol containing building block prepared from d-ribose. While a ring-closing metathesis approach did not lead to the macrocycle, alkylation of a benzyl(phenyl)selane, elimination to generate the styrene double bond, followed by Mitsunobu macrolactonization proved to be successful. Spectral data suggest that the structure of queenslandon should be revised, probably to the C11 epimer.

Ga(IIl)-catalyzed cycloisomerization approach to (±)-icetexone and (±)-epi-icetexone

"Chemical eqation presented" A Ga(III)-catalyzed cycloisomerization reaction provides expedient access to a benzannulated cycloheptadiene bearing a cyano group, which has been applied to the syntheses of several icetexane diterpenoids including icetexone

MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS

The present invention provides compounds having formula (I), and additionally provides methods for the synthesis thereof and methods for the use thereof in the treatment of various disorders including inflammatory or autoimmune disorders, and disorders involving malignancy or increased angiogenesis, wherein R1 -R11, t, X, Y, Z, and n are as defined herein.

A concise and efficient synthesis of protected actinoidic acid, the degradation product of vancomycin

Protected actinoidic acid 2, one of the degradation products of vancomycin, has been efficiently synthesized by a convergent route which is amenable to large scale application as well as to asymmetric synthesis.

FORMAL TOTAL SYNTHESIS OF β-PIPITZOL

(+/-)-O-methylperezone (1b) was obtained by selective oxidative demethylation of (+/-)-leucoperezone trimethyl ether (4a).Compound (4a) was prepared by condensation of 2,3,5-trimethoxytoluene (5e) with 6-methyl-5-heptene-2-one, followed by reductive removal of the tertiary alcohol.The aromatic precursor 5e was prepared in four steps from 2,3-dimethoxytoluene (5a) and, alternatively, in three steps from 5-bromoveratraldehyde (6a).Racemic 1b and 4a were directly compared with the optically active molecules prepared from natural R(-)-perezone (1a).